Physician profile
Priya Malik
NPI 1811001506
$1,338.38
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $180 · 2020: $417 · 2021: $347 · 2022: $189 · 2023: $183 · 2024: $22.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $205.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $487.83 | 2020-2024 | |
| Lilly USA, LLC | $184.23 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $135.09 | 2019-2021 | |
| Eisai INC. | $125.30 | 2020-2021 | |
| Upsher-Smith Laboratories LLC | $85.10 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.49 | 2021 | |
| Arbor Pharmaceuticals, INC. | $33.31 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $29.06 | 2021 | |
| Amgen INC. | $25.77 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $25.29 | 2020 | |
| Alnylam Pharmaceuticals INC. | $21.34 | 2020 | |
| Janssen Pharmaceuticals, INC | $21.10 | 2021 | |
| Sanofi-Aventis U.S. LLC | $19.73 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.91 | 2021 | |
| Glaxosmithkline, LLC. | $15.63 | 2023 | Bexsero |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermira, INC. | $15.19 | 2020 | |
| Therapeuticsmd, INC. | $15.13 | 2020 | |
| Pfizer INC. | $12.88 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Priya Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.